Please login to the form below

Not currently logged in
Email:
Password:

rivaroxaban

This page shows the latest rivaroxaban news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Latest news

More from news
Approximately 9 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Rivaroxaban. Rivaroxaban (Xarelto; Bayer and Johnson &Johnson) is an oral, once-daily, selective factor Xa inhibitor that is approved in the EU and US for the prevention of stroke and systemic ... In addition, rivaroxaban significantly reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics